Is Dapagliflozin a medical insurance drug?

Dapagliflozin is a drug used to treat diabetes and belongs to a class of drugs called SGLT-2 inhibitors (sodium-glucose cotransporter-2 inhibitors). SGLT-2 is a protein in the kidneys that regulates the reabsorption of glucose in the body. By inhibiting the function of SGLT-2, dapagliflozin can cause the kidneys to reduce the reabsorption of glucose, thereby increasing the excretion of glucose from the body through the urine, thereby lowering blood sugar levels.

Dapagliflozin has been launched in China and has been included in medical insurance. Patients can purchase it domestically. The domestic price is relatively cheap. Please consult the local hospital pharmacy or medical insurance bureau for specific prices and reimbursement policies.

Dapagliflozin is primarily used to treat type 2 diabetes, a chronic disease in which the body cannot effectively use insulin to control blood sugar levels. It is often used as a supplement to non-drug treatments such as diet and exercise deficiencies, and may also be used with other anti-diabetic medications. Dapagliflozin can lower blood sugar, promote weight loss, and has been shown to have a protective effect against cardiovascular events in some studies.

However, as a drug, dapagliflozin also has some potential side effects and risks, including urinary tract infection, risk of hypoglycemia (when used in combination with certain other drugs), hypovolemia, increased uric acid, etc. Therefore, when using dapagliflozin or other drugs, it should be done according to the guidance and supervision of your doctor.